Corrigendum: Lower serum insulin-like growth factor 2 level in patients with bipolar disorder is associated with the severity of manic symptoms during manic episodes.

[This corrects the article DOI: 10.3389/fpsyt.2024.

Lower serum insulin-like growth factor 2 level in patients with bipolar disorder is associated with the severity of manic symptoms during manic episodes.

Objective: Accumulating evidence has indicated that neurodevelopmental defects may underlie the pathophysiology of bipolar disorder (BD). Insulin-like growth factors (IGFs) are a family of neurotrophic factors that are essential for the survival and development of neurons. The present study aims to investigate whether IGF-2 signaling is implicated in the pathophysiological processes of BD.

[Expression and prognostic value of IL-6 and β-catenin in oral squamous cell carcinoma].

Purpose: To investigate the expression of interleukin-6 (IL-6) and β-catenin in oral squamous cell carcinoma (OSCC) and its clinicopathological significance.

Methods: The serum IL-6 concentration in 110 OSCC patients and 109 healthy controls were determined by chemiluminescence analysis. IL-6 and β-catenin expression levels in 68 tumor specimens of OSCC patients undergoing surgical treatment and 6 normal mucosal tissues were determined by immunohistochemistry method.

Reducing coherent noise in interference systems using the phase modulation technique.

The phase modulation technique is adopted to reduce the coherent noise that arises from spurious interference. By choosing an appropriate driving signal, the method can reduce the coherent function of coherent noise to a great degree while keeping the coherent function of a coherent signal nearly unchanged. Simulation results show that for the grating interferometer, the phase error caused by coherent noise is reduced by 81.

NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery.

NY-ESO-1 belongs to the cancer testis antigens (CTA) family, and is identified in a variety of tumors. Certain studies have demonstrated that NY-ESO-1 predicts tumor recurrence and treatment response. No reports are currently available regarding the correlation between NY-ESO-1 and the recurrence of hepatocellular carcinoma (HCC) following surgery.